The exclusive antagonistic action exerted by MIBE on both ERα and GPER could represent a novel promising tool for a more comprehensive pharmacological approach in estrogen-dependent tumors like breast cancer, which express one or both receptors from the onset or following tumor progression. The gene discussed is ESR1; the disease is breast carcinoma.